Gene-expression profiling and array-based CGH classify CD4 +CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities

Blood

Volumn 109, Issue 4, 2007, Pages 1720-1727

  Dijkman, Remco ^a   Van Doorn, Remco ^a   Szuhai, Károly ^a   Willemze, Rein ^a   Vermeer, Maarten H ^a   Tensen, Cornelis P ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; GENE PRODUCT; PROTEIN HES6; PROTEIN LATS2; PROTEIN RB1; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GENETICS; CHILD; CHROMOSOME 9; CHROMOSOME ABERRATION; CHROMOSOME DELETION 13; CHROMOSOME DELETION 4; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENOME ANALYSIS; HEMATODERMIC NEOPLASM; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; MYELOMONOCYTIC LEUKEMIA; ONCOGENE; PRIORITY JOURNAL; SKIN BIOPSY; SKIN TUMOR; TUMOR SUPPRESSOR GENE;

EID: 33846456740     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-04-018143     Document Type: Article

References (34)

1. Petrella T, Comeau MR, Maynadie M, et al. 'Agranular CD4+ CD56+ hematodermic neoplasm' (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol. 2002;26:852-862.
2. Bekkenk MW, Jansen PM, Meijer CJ, Willemze R. CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol. 2004;15:1097-1108.
3. Petrella T, Bagot M, Willemze R, et al. Blastic NKcell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol. 2005;123:662-675.
4. Jacob MC, Chaperot L, Mossuz P, et al. CD4+ CD56+ lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells. Haematologica. 2003;88:941-955.
5. Urosevic M, Conrad C, Kamarashev J, et al. CD4+CD56+ hematodermic neoplasms bear a plasmacytoid dendritic cell phenotype. Hum Pathol. 2005;36:1020-1024.
6. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768-3785.
7. Hallermann C, Middel P, Griesinger F, et al. CD4+ CD56+ blastic tumor of the skin: cytogenetic observations and further evidence of an origin from plasmocytoid dendritic cells. Eur J Dermatol. 2004;14:317-322.
8. Leroux D, Mugneret F, Callanan M, et al. CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Francais de Cytogenetique Hematologique. Blood. 2002;99:4154-4159.
9. Mao X, Onadim Z, Price EA, et al. Genomic alterations in blastic natural killer/extranodal natural killer-like T cell lymphoma with cutaneous involvement. J Invest Dermatol. 2003;121:618-627.
10. Hoefnagel JJ, Dijkman R, Basso K, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood. 2005;105:3671-3678.
11. Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute. Available at: http://linus.nci.nih.gov/BRBArrayTools. html. Accessed March 2006.
12. Department of Biostatistics. Harvard School of Public Health.Available at: http://biosun1.harvard.edu/complab/dchip. Accessed March 2006.
13. Li C, Hung Wong W. Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol. 2001;2:RESEARCH0032.
14. Genomics Institute of the Novartis Research Foundation. Available at: http://wombat.gnf.org/SymAtlas. Accessed March 2006.
15. Knijnenburg J, Szuhai K, Giltay J, et al. Insights from genomic microarrays into structural chromosome rearrangements. Am J Med Genet A. 2005;132:36-40.
16. Sanger Centre and the European Molecular Biology Laboratory-European Bioinformatics Institute. Available at: http://www.ensembl.org. Accessed March 2006.
17. Dijkman R, Tensen CP, Jordanova ES, et al. Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma. J Clin Oncol. 2006;24:296-305.
18. Bakker AB, Baker E, Sutherland GR, Phillips JH, Lanier LL. Myeloid DAP12-associating lectin (MDL)-1 is a cell surface receptor involved in the activation of myeloid cells. Proc Natl Acad Sci U S A. 1999;96:9792-9796.
19. Miranda RN, Briggs RC, Shults K, et al. Immunocytochemical analysis of MNDA in tissue sections and sorted normal bone marrow cells documents expression only in maturing normal and neoplastic myelomonocytic cells and a subset of normal and neoplastic B lymphocytes. Hum Pathol. 1999;30:1040-1049.
20. Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med. 2001;194:863-869.
21. Schotte R, Nagasawa M, Weijer K, Spits H, Blom B. The ETS transcription factor Spi-B is required for human plasmacytoid dendritic cell development. J Exp Med. 2004;200:1503-1509.
22. Chaperot L, Bendriss N, Manches O, et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood. 2001;97:3210-3217.
23. Nam Y, Aster JC, Blacklow SC. Notch signaling as a therapeutic target. Curr Opin Chem Biol. 2002;6:501-509.
24. Vasiliauskas D, Stern CD. Expression of mouse HES-6, a new member of the Hairy/Enhancer of split family of bHLH transcription factors. Mech Dev. 2000;98:133-137.
25. Pissarra L, Henrique D, Duarte A. Expression of hes6, a new member of the Hairy/Enhancer-of-split family, in mouse development. Mech Dev. 2000;95:275-278.
26. Bae S, Bessho Y, Hojo M, Kageyama R. The bHLH gene Hes6, an inhibitor of Hes1, promotes neuronal differentiation. Development. 2000;127:2933-2943.
27. Chen H, Thiagalingam A, Chopra H, et al. Conservation of the Drosophila lateral inhibition pathway in human lung cancer: a hairy-related protein (HES-1) directly represses achaete-scute homolog-1 expression. Proc Natl Acad Sci U S A. 1997;94:5355-5360.
28. Vaillant F, Blyth K, Andrew L, Neil JC, Cameron ER. Enforced expression of Runx2 perturbs T cell development at a stage coincident with beta-selection. J Immunol. 2002;169:2866-2874.
29. Blyth K, Terry A, Mackay N, et al. Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene. 2001;20:295-302.
30. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3:650-665.
31. Birg F, Courcoul M, Rosnet O, et al. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood. 1992;80:2584-2593.
32. Levis M, Allebach J, Tse KF, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 2002;99:3885-3891.
33. Schlomm T, Luebke AM, Sultmann H, et al. Extraction and processing of high quality RNA from impalpable and macroscopically invisible prostate cancer for microarray gene expression analysis. Int J Oncol. 2005;27:713-720.
34. Varki A, Angata T. Siglecs - the major subfamily of I-type lectins. Glycobiology. 2006;16:1R-27R.